

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/725,574	12/03/2003	Gudmundur Fertram Sigurjonsson	SIGU3011/JJC	5131
23364 BACON & TE	7590 12/02/200 IOMAS, PLLC	EXAMINER		
625 SLATERS LANE			HAND, MELANIE JO	
FOURTH FLO	OR A, VA 22314-1176	ART UNIT	PAPER NUMBER	
, mannin dord	.,		3761	•
			MAIL DATE	DELIVERY MODE
			12/02/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/725,574	SIGURJONSSON ET AL.	
Examiner	Art Unit	
MELANIE J. HAND	3761	

•	LAUIIIIICI	7.11.01.11.	
	MELANIE J. HAND	3761	
The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence ado	ress
THE REPLY FILED 27 October 2008 FAILS TO PLACE THIS A	APPLICATION IN CONDITION FOR	R ALLOWANCE.	
<ol> <li>N he reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of App for Continued Examination (RCE) in compliance with 37 of periods:</li> </ol>	replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	t, or other evidence, v with 37 CFR 41.31; o	which places the r (3) a Request
The period for reply expiresmonths from the mailing	date of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I	dvisory Action, or (2) the date set forth		
Examiner Note: If box 1 is checked, check either box (a) or MONTHS OF THE FINAL REJECTION. See MPEP 706.07(	f).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL.	tension and the corresponding amount shortened statutory period for reply origing than three months after the mailing date	of the fee. The appropri nally set in the final Office	ate extension fee be action; or (2) as
The Notice of Appeal was filed on A brief in comp	liance with 37 CFR 41.37 must be	filed within two month	s of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any exte Notice of Appeal has been filed, any reply must be filed w AMENDMENTS	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
The proposed amendment(s) filed after a final rejection,	out prior to the date of filing a brief	will not be entered be	cause
(a) ☐ They raise new issues that would require further co			, cause
(b) They raise the issue of new matter (see NOTE belo			
(c) ☐ They are not deemed to place the application in bet appeal; and/or	ter form for appeal by materially red	ducing or simplifying t	he issues for
(d) ☐ They present additional claims without canceling a		ected claims.	
NOTE: See Continuation Sheet. (See 37 CFR 1.1			
<ol> <li>The amendments are not in compliance with 37 CFR 1.1.</li> </ol>		mpliant Amendment (	PTOL-324).
<ol> <li>Applicant's reply has overcome the following rejection(s)</li> </ol>			
<ol> <li>Newly proposed or amended claim(s) would be al  non-allowable claim(s).</li> </ol>		•	
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is profile status of the claim(s) is (or will be) as follows:		I be entered and an e	xplanation of
Claim(s) allowed:			
Claim(s) objected to: Claim(s) rejected: 12.14-16.18-20.23.			
Claim(s) rejected: 12.14-16.16-20.23. Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
<ol> <li>The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).</li> </ol>			
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessar</li> </ol>	vercome all rejections under appea	al and/or appellant fail	s to provide a
<ol> <li>The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER</li> </ol>	n of the status of the claims after er	ntry is below or attach	ed.
The request for reconsideration has been considered bu See Continuation Sheet.	t does NOT place the application in	condition for allowar	ce because:
<ol> <li>Note the attached Information Disclosure Statement(s).</li> </ol>	(PTO/SB/08) Paper No(s). 9/24/08		
13. 🔲 Other:			
/Tatyana Zalukaeva/	/Melanie J Hand/		
Supervisory Patent Examiner, Art Unit 3761	Examiner, Art Unit 3761		

U.S. Patent and Trademark Office

Examiner, Art Unit 3761

Continuation of 3. NOTE: Applicant amended independent claim 12 to recite that the second facing layer is coplanar with the proximal surface of the first facing layer, rather than generally coplanar, which narrows the scope of the claim, causing further search and consideration after a final action was mailed. This limitation, as well as the amendment to the specification, introduces new matter. Examiner's position is based upon applicant's original disclosure that the first skin-facing layer defines a portion of the boody-facing surface of the wound dressing and that the second facing layer is directly bonded to and coextensive with said proxile jurface. It is not possible for a layer of any thickness that is bonded to such surface to also be coplanar with said surface. Thus, the amendments to the claims and specification introduce new matter and will not be entered.

Continuation of 11, does NOT place the application in condition for allowance because: Applicant's arguments with respect to the specification have been fully considered aumanded claim 12 have been fully considered but ane not persuasive. Examiner disagrees with applicant's argument that amending claim 12 to recite that the second facing layer is coplanar with the first facing layer does not introduce new matter. Such a limitation narrows the scope of the claim and is not supported by the disclosure as originelled. With respect to arguments regarding claim 23 the same embodiment of the dressing of Lawry can be used against both claim 12 and 23 because claims 23 comprises a first skin facing layer, i.e. any prior art having addition layers will still be valid prior art against the sims. Examiner did not assert that a combination of layers 16 and 26 met the limitation of the claimed single facing layer, only layer 16. Applicant's argument that Lawry does not teach a silicone facing layer with apertures, first, the references cited by applicant in the Remains are two isolated references whose teachings are not relevant to the teachings of Lawry. Second, there is no limitation in claim 23 as to impregnation or how the gel layer is formed and even if there were, it would be a product-by process limitation, still rejected over Lawry alone. Lawry clearly discloses apertures in a gel layer, i.e. the entire layer is gel, and the apertures are formed in the gel layer. Thus the non-apertured portions necessarily consist of the gel compound that forms the entire layer.